A ray of hope in the discord: is adding piperacillin-tazobactam to vancomycin truly more nephrotoxic?

Jean-Maxime Côté^{1

2}, Sandra L Kane-Gill^{3

4}, Patrick T Murray^{5

6}

Affiliations

¹ Division of Nephrology, Department of Medicine, Centre Hospitalier de L'Université de Montréal, Montréal, Canada.
² Clinical Research Center (CrCHUM), Centre Hospitalier de L'Université de Montréal, Montréal, Canada.
³ Department of Pharmacy and Therapeutics, Department of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA, USA.
⁴ Program for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
⁵ School of Medicine, University College Dublin, Dublin, Ireland. patrick.murray@ucd.ie.
⁶ Division of Nephrology, Mater Misericordiae University Hospital, Dublin, Ireland. patrick.murray@ucd.ie.

Editorial

Jean-Maxime Côté et al. Intensive Care Med. 2022 Sep.

. 2022 Sep;48(9):1208-1210.

doi: 10.1007/s00134-022-06861-4. Epub 2022 Aug 31.

Jean-Maxime Côté^{1

2}, Sandra L Kane-Gill^{3

4}, Patrick T Murray^{5

6}

¹ Division of Nephrology, Department of Medicine, Centre Hospitalier de L'Université de Montréal, Montréal, Canada.
² Clinical Research Center (CrCHUM), Centre Hospitalier de L'Université de Montréal, Montréal, Canada.
³ Department of Pharmacy and Therapeutics, Department of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA, USA.
⁴ Program for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
⁵ School of Medicine, University College Dublin, Dublin, Ireland. patrick.murray@ucd.ie.
⁶ Division of Nephrology, Mater Misericordiae University Hospital, Dublin, Ireland. patrick.murray@ucd.ie.

No abstract available

Comment on

Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study.
Miano TA, Hennessy S, Yang W, Dunn TG, Weisman AR, Oniyide O, Agyekum RS, Turner AP, Ittner CAG, Anderson BJ, Wilson FP, Townsend R, Reilly JP, Giannini HM, Cosgriff CV, Jones TK, Meyer NJ, Shashaty MGS. Miano TA, et al. Intensive Care Med. 2022 Sep;48(9):1144-1155. doi: 10.1007/s00134-022-06811-0. Epub 2022 Jul 14. Intensive Care Med. 2022. PMID: 35833959 Free PMC article.

1. Bellos I, Karageorgiou V, Pergialiotis V et al (2020) Acute kidney injury following the concurrent administration of antipseudomonal beta-lactams and vancomycin: a network meta-analysis. Clin Microbiol Infect 26(696–705):20200325. https://doi.org/10.1016/j.cmi.2020.03.019 - DOI
1. Cook KM, Gillon J, Grisso AG et al (2019) Incidence of nephrotoxicity among pediatric patients receiving vancomycin with either piperacillin-tazobactam or cefepime: a cohort study. J Pediatric Infect Dis Soc 8:221–227. https://doi.org/10.1093/jpids/piy030 - DOI - PubMed
1. Downes KJ, Cowden C, Laskin BL et al (2017) Association of acute kidney injury with concomitant vancomycin and Piperacillin/Tazobactam treatment among hospitalized children. JAMA Pediatr 171(e173219):20171204. https://doi.org/10.1001/jamapediatrics.2017.3219 - DOI
1. Blair M, Cote JM, Cotter A et al (2021) Nephrotoxicity from vancomycin combined with Piperacillin-Tazobactam: a comprehensive review. Am J Nephrol 52(85–97):20210318. https://doi.org/10.1159/000513742 - DOI
1. Kang S, Park J, Yu YM et al (2019) Comparison of acute kidney injury and clinical prognosis of vancomycin monotherapy and combination therapy with beta-lactams in the intensive care unit. PLoS ONE 14(e0217908):20190605. https://doi.org/10.1371/journal.pone.0217908 - DOI